Device Trial Radar · NCT04277416
Survivorship and Effectiveness of the Ortho Development® Entrada™ Hip System for Total Hip Arthroplasty
Last checked: Nov 19, 2026Latest source record: Oct 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
250
Planned (sponsor's estimate)
Start
Feb 28, 2020
Primary completion
Dec 31, 2031
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- Ortho Development CorporationNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Oregon Health and Science University
- First posted
- Feb 20, 2020
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate Implant survival based on removal or intended removal of any component of the Entrada™ Hip System at five years of follow-up.
Conditions
- Total Hip Replacement
- Total Hip Arthroplasty
Interventions
Total Hip ArthroplastyDevice
To evaluate Implant survival based on removal or intended removal of any component of the Entrada™ Hip System at five years of follow-up.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Implant SurvivalTime frame: 5 - 10-year follow-up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Oregon Health Sciences University
Portland, Oregon
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.